Posted by Michael Wonder on 26 Oct 2018
AbbVie’s CLL drug Venclyxto too expensive for NHS, says NICE
26 October 2018 - NICE has said AbbVie’s Venclyxto (venetoclax), in combination with development partner Roche’s MabThera/Rituxan (rituximab), is not a cost-effective use of NHS resources as a treatment for a kind of leukaemia.
The cost-effectiveness body said in first draft guidance that the combination should not receive regular NHS funding in relapsed or refractory chronic lymphocytic leukaemia in adults.
In the guidance, NICE noted that people with this form of the disease have limited treatment options – it progresses slowly and patients are left for a long time in the “watch and wait” stage of the treatment pathway.
